Connect with us

Press Release

CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

Published

3 months ago

on

SHENZHEN, CHINA – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.

As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.

The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).

Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.

As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].

It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.

The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

  1. China Insights Consultancy’s industrial report
  2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.
  3. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

  1. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Sean Powers Examines Emerging Trends in Global Sourcing and Supply Chain Management

Published

40 minutes ago

on

June 19, 2026

By

  • Chicago Business Professional Shares Perspectives on Adaptability, Supplier Relationships, and Operational Resilience.

CHICAGO, IL, Jun 19, 2026, ZEX PR WIRE — Sean Powers, a Chicago-based business professional with experience in pipeline operations, manufacturing, international sourcing, and sales, is sharing his perspective on the evolving landscape of global sourcing and supply chain management as businesses continue adapting to changing market conditions.

Drawing on years of experience working across multiple industries, Powers believes organizations are increasingly prioritizing resilience, communication, and flexibility as they navigate ongoing supply chain challenges and opportunities.

“The conversation around supply chains has changed significantly over the last several years,” said Powers. “Companies are paying closer attention to how products move, where materials come from, and how supplier relationships affect long-term business performance.”

Global sourcing has long played an important role in helping businesses access materials, products, and manufacturing capabilities around the world. However, recent disruptions have prompted many organizations to reevaluate sourcing strategies and place greater emphasis on diversification and operational preparedness.

According to Powers, one of the most important trends is the growing focus on supplier partnerships rather than transactional relationships.

“Strong supplier relationships create stability,” Powers explained. “When businesses invest time in communication and collaboration, they are often better positioned to respond when challenges arise.”

Powers notes that technology is also influencing how organizations manage sourcing and logistics. Increased visibility into supply chains allows companies to make more informed decisions and identify potential issues earlier in the process.

“Access to information has improved dramatically,” he said. “Businesses can monitor operations more closely than ever before. The key is using that information to make practical decisions rather than simply collecting data.”

Throughout his career, Powers has worked in environments where operational efficiency and coordination directly impacted business outcomes. Those experiences have shaped his view that successful supply chain management requires balancing strategy with execution.

“Planning is important, but execution is what ultimately delivers results,” Powers said. “Organizations need systems in place, but they also need people who can communicate effectively and solve problems when unexpected situations occur.”

Another trend Powers sees gaining momentum is the emphasis on adaptability. As markets continue to evolve, businesses are increasingly looking for sourcing strategies that can accommodate changing customer demands, shifting regulations, and economic uncertainty.

“Adaptability has become a competitive advantage,” Powers said. “Companies that can respond quickly while maintaining quality and reliability are often better equipped for long-term success.”

Powers also believes that despite advances in technology, human relationships remain a critical component of effective sourcing and supply chain operations.

“Technology can improve efficiency, but business still comes down to people,” he said. “Trust, communication, and accountability continue to play a major role in successful partnerships.”

Having worked across operations, manufacturing, sourcing, and sales, Powers has developed a broad perspective on how different parts of an organization contribute to overall performance. He believes that collaboration between departments is becoming increasingly important as businesses seek greater efficiency and visibility across their operations.

“The strongest organizations understand how interconnected everything is,” Powers said. “Decisions made in one area often affect multiple parts of the business. The more alignment there is, the better the outcomes tend to be.”

Looking ahead, Powers expects global sourcing and supply chain management to remain a major area of focus for organizations seeking to strengthen operations and improve responsiveness in an increasingly complex business environment.

“Every challenge creates an opportunity to improve,” he said. “The organizations that continue learning, adapting, and building strong relationships will be the ones best positioned for the future.”

About Sean Powers

Sean Powers is a Chicago-based business professional with experience in pipeline operations, manufacturing, international sourcing, and sales. Throughout his career, he has worked across multiple industries, focusing on operational execution, relationship development, problem-solving, and business growth.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Centar Klima Prepares Homes and Businesses for Summer 2026 with Reliable Air Conditioning Solutions

Published

3 hours ago

on

June 19, 2026

By

Zagreb-based air conditioning company offers sales, expert guidance, installation, maintenance, and servicing for residential and commercial customers.

Zagreb, Zagreb, Croatia (Hrvatska), 19th Jun 2026 – As summer temperatures continue to rise, Centar Klima is preparing homeowners, apartment owners, offices, and businesses across Croatia with a wide selection of air conditioning solutions for the 2026 cooling season.

Centar Klima offers air conditioning units from well-known global brands, including Bosch, Daikin, LG, Mitsubishi Electric, Samsung, Toshiba, and Vivax. With a range of models, capacities, and price points available, customers can find a suitable system based on the size of their space, cooling and heating requirements, energy efficiency expectations, and budget.

In addition to selling air conditioning units, Centar Klima provides professional guidance, installation, maintenance, repair, and servicing. The company’s goal is to make the entire process easier for customers, from choosing the right unit to ensuring proper installation and long-term performance.

Choosing the Right Air Conditioner Can Improve Comfort and Reduce Energy Use

Selecting an air conditioning unit should not be based on price alone. The size of the room, insulation quality, layout, sun exposure, number of occupants, and intended use all play an important role in determining the most suitable system.

An undersized air conditioner may need to operate continuously to reach the desired temperature, while an oversized unit may increase the initial investment and reduce comfort due to frequent cycling.

“Customers often contact us because they are unsure which air conditioning unit is the right choice for their home, apartment, or office. Our goal is to recommend a solution that provides reliable cooling, efficient energy use, quiet operation, and long-term value,” said Ivan at Centar Klima.

Modern inverter air conditioners automatically adjust compressor operation according to the needs of the room. This allows them to maintain a more stable temperature, reduce unnecessary energy consumption, and deliver more comfortable performance compared to older, conventional systems.

Many modern units are also suitable for more than just cooling. Thanks to heating functionality, air conditioners can be used during transitional seasons and, in some spaces, as an additional heating source during colder months.

Air Conditioning Solutions for Different Types of Spaces

Centar Klima offers air conditioning systems suitable for bedrooms, children’s rooms, apartments, home offices, living rooms, rental properties, and larger commercial spaces.

Customers looking for a practical and cost-effective solution can choose from reliable entry-level inverter models, while more advanced units may include features such as Wi-Fi control, improved filtration, quiet operation, advanced airflow control, and higher energy efficiency.

When choosing an air conditioner, customers should consider:

  • The recommended room size
  • Cooling and heating capacity
  • Energy efficiency rating
  • Indoor unit noise level
  • Wi-Fi control options
  • Warranty terms
  • Installation requirements
  • Maintenance and servicing availability

Professional advice before purchase helps reduce the risk of choosing a unit that is not properly matched to the space or the customer’s expectations.

Regular Maintenance Supports Better Performance and Cleaner Air

Along with proper selection and professional installation, regular maintenance is essential for keeping an air conditioning system efficient, hygienic, and reliable.

Over time, dust and other particles can accumulate on filters, the evaporator, and other internal components. A poorly maintained unit may cool less effectively, consume more energy, produce unpleasant odors, or affect indoor air quality.

A standard service usually includes inspection of the unit’s operation, cleaning of the indoor and outdoor units, checking the condensate drain, and reviewing key system performance parameters.

Centar Klima recommends servicing air conditioners at least once per year, ideally before the start of the main cooling season. In spaces where air conditioners are used daily, such as offices, apartments, rental properties, and hospitality facilities, more frequent maintenance may be recommended.

Early Preparation Before Peak Summer Demand

During the hottest weeks of summer, demand for air conditioning units, installation, and servicing can increase significantly. For this reason, Centar Klima encourages customers to plan their purchase, installation, or annual maintenance before the first major heatwave.

Early preparation gives customers more time to compare models, receive expert advice, schedule installation, and make a confident decision without the pressure of peak-season demand.

Customers can view available air conditioning units and learn more about Centar Klima’s services at centarklima.com. For advice, installation, repairs, or servicing, customers can contact the Centar Klima team directly.

About Centar Klima

Centar Klima is a Zagreb-based air conditioning company specializing in the sale, installation, repair, maintenance, and servicing of air conditioning units. Operating as part of Smart Switch d.o.o., the company has more than ten years of experience helping residential and commercial customers choose and maintain reliable climate control solutions.

Centar Klima offers air conditioning units from leading global manufacturers and provides professional support for different types of homes, apartments, offices, and business spaces.

Website: https://centarklima.com/ 

 

Media Contact

Organization: Centar Klima

Contact Person: Ivan Juric

Website: https://centarklima.com/

Email: Send Email

Contact Number: +385955444123

Address:Bozidara Magovca 39

City: Zagreb

State: Zagreb

Country:Croatia (Hrvatska)

Release id:46260

The post Centar Klima Prepares Homes and Businesses for Summer 2026 with Reliable Air Conditioning Solutions appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Stratosphere, Pudgy Penguins and Streamex Host Founders Table VIP Dinner During ETHConf 2026 and NYC Tech Week

Published

3 hours ago

on

June 19, 2026

By

New York, United States, June 18th, 2026, Chainwire

Stratosphere, Pudgy Penguins and Streamex hosted a private Founders Table VIP Dinner in New York City during ETHConf 2026 and NYC Tech Week, bringing together leaders across digital assets, tech, AI, traditional finance and institutional capital.

The invite-only dinner took place on June 9th and gathered a curated room of founders, operators, funds, C-level executives and institutional leaders for an intimate evening of dinner and conversation.

Guests in attendance included leaders from Citi, BitMine, BitGo, Mirae Asset Securities USA, Experian, Pyth Network, Space and Time, MegaETH, B3, Stable, Antler, Delphi Digital, Fun, Linera, Vanta Trading, Streamex, PolyData, Horizen Labs, World Foundation, Zipcode, OpenLedger, Onyx, Definitive, Notalone Ventures and more.

The Founders Table format is intentionally simple: a selected guest list, a private room and no stage agenda. The goal is to bring the right people together in a setting where conversations can happen naturally.

The dinner was hosted by Stratosphere with Pudgy Penguins and Streamex. Stratosphere brought its network across founders, operators, investors and institutional teams. Pudgy Penguins added one of the strongest consumer brands and communities in digital assets. Streamex brought the institutional and real-world asset side of the conversation, with its focus on tokenized gold and commodity markets.

The Stratosphere team and its CEO, Hassan Shaikh, have continued to build Founders Table into a private dinner series around major industry conferences. After previous editions during Digital Asset Summit and Consensus, the New York dinner continued the same idea: high-quality rooms, selected attendance and conversations that are hard to recreate on a conference floor.For Stratosphere, the dinner reinforces the company’s position as an ecosystem partner for leading brands across tech, finance and digital assets. Established projects work with Stratosphere to deepen cultural relevance, strengthen market narratives and connect with founders, investors, institutions and operators across the industry.

“I’m optimistic about the next phase of digital assets, especially around the tokenization of commodities,” said Hassan Shaikh, CEO of Stratosphere. “These dinners give us a way to bring funds, institutions, and founders into the same room to talk about where the market is heading.”

The Founders Table series is expected to continue around major global conferences throughout the year, with future editions focused on bringing together founders, capital, institutions and leading brands in private, relationship-driven rooms.

For those interested in attending or getting involved in future Founders Table editions, reach out to the Stratosphere team.

About Stratosphere

Stratosphere is an ecosystem partner and growth consultancy for industry leaders in tech and finance, building the narratives, ecosystem partnerships, and distribution flywheels that create sustainable, repeatable growth.

Website: www.stratosphere.vip

X: @StratosphereVIP

Contact

Yaroslav Provada
max@movimentum.io

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us